Renaissance Capital logo

TCRX News

US IPO Weekly Recap: The summer IPO market heats up in a 13 IPO week

STVN

After a slow start to the month, the IPO market revved back to life with 13 IPOs coming to market this past week. SPAC activity picked up, with seven blank check IPOs raising $940 million. New filers continued to flood the IPO pipeline, with fourteen IPOs and...read more

Preclinical cancer biotech TScan Therapeutics prices IPO at $15 low end

TScan Therapeutics logo

TScan Therapeutics, a preclinical biotech developing engineered T cell cancer therapies, raised $100 million by offering 6.7 million shares at $15, the low end of the range of $15 to $17. The company had previously filed to offer 6.3 million shares, but...read more

Preclinical oncology biotech TScan Therapeutics sets terms for $100 million IPO

TScan Therapeutics logo

TScan Therapeutics, a preclinical biotech developing engineered T cell cancer therapies, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the...read more

US IPO Week Ahead: Real estate, post-pandemic plays and more in a 15 IPO week

STVN

Updated Monday, 7/12. After a slow holiday week, 15 IPOs are scheduled to raise nearly $4 billion in the week ahead. A handful of SPACs should also price. Italian drug container supplier Stevanato Group (STVN) plans to raise $900...read more